What is Almirall?
operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa.
0O9B · Verdict
Moderate reward · low risk
0O9B stands out on cash flow and volatility, but watch the profitability signal.
Based on 75% data coverage
0O9B · Verdict
Top decile vs peers
Top decile vs peers
Current ratio 2.01
3% return on equity
Model-based scoring. For information only — not financial advice.
operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal system, nervous system, respiratory system, systemic hormonal preparations. The company is listed on the LSE in UK, with a market capitalisation of 1.81B.
The scoring profile indicates limited reward potential at this time, with growth and valuation offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.
For informational purposes only. Not financial advice.